Change and Innovation - BioPharm International is the longest-running peer-reviewed publication dedicated to your work - BioPharm International

ADVERTISEMENT

Change and Innovation
BioPharm International is the longest-running peer-reviewed publication dedicated to your work


BioPharm International
Volume 24, Issue 3, pp. 8


Allen Basis
Recently we announced the appointment of Michelle Hoffman as Editorial Director of Advanstar's Pharmaceutical Drug Development and Manufacturing Group, which now includes BioPharm International, Pharmaceutical Technology, Pharmaceutical Technology Europe, and the IVT Journals. I am pleased to join Ms. Hoffman as BioPharm International's new publisher.

It is exciting to work with an editor whose curriculum vita matches our tagline, "The Science & Business of Pharmaceuticals." Michelle's appointment and my employment and dedication to BioPharm International are examples of an evolving list of investments Advanstar Communications, our parent, is making in the brand. With more than 20 years of media management, I am dedicated to developing new and innovative ways of delivering the content you've come to depend on in print and online.

BioPharm International is the longest-running peer-reviewed publication dedicated to facilitating your work in the development and manufacturing of biotherapeutics and managing related business issues. Our goal is to provide the most up-to-date, reliable, and insightful information available to you in the biopharmaceutical market. To ensure that we meet your needs, I will seek your opinions about our performance.

We strive to equip you to manage your technical and business challenges effectively, but if we can serve you better with more news and information on tools, techniques, or business, we invite you to please let us know. Please drop us a line and be sure to look for us at industry conferences and expos throughout the year.

All the best,

Allen Basis is the publisher of BioPharm International,
.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here